2. Search Result
Search Result
Results for "

anti-apoptotic effect

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

2

Peptides

6

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108635
    C16-PAF
    35+ Cited Publications

    PAF (C16)

    		 p38 MAPK MEK ERK Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability .
    C16-PAF
  • HY-108521
    HX531

    		RAR/RXR Apoptosis MDM-2/p53 Metabolic Disease Cancer
    HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities .
    HX531
  • HY-B0612A
    Lercanidipine hydrochloride
    1 Publications Verification

    		 Calcium Channel Apoptosis Reactive Oxygen Species (ROS) p38 MAPK NF-κB Cardiovascular Disease Neurological Disease
    Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
    Lercanidipine hydrochloride
  • HY-B0612
    Lercanidipine
    1 Publications Verification

    		 Calcium Channel Apoptosis Reactive Oxygen Species (ROS) p38 MAPK NF-κB Cardiovascular Disease Neurological Disease
    Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
    Lercanidipine
  • HY-P1928
    Humanin

    		Bcl-2 Family Neurological Disease Endocrinology
    Humanin, an anti-apoptotic peptide of 24 amino acids, is a Bax inhibitor. Humanin prevents the translocation of Bax from cytosol to mitochondria, blocks Bax from the inactive to active conformation. Humanin is a mitochondria-associated peptide with a neuroprotective effect against AD-related neurotoxicity. Humanin also improves overall insulin sensitivity in animal. Humanin are related to aging .
    Humanin analogue, in which the serine at position 14 is replaced by glycine, names HNG .
    Humanin
  • HY-162858
    BRD-810

    		Bcl-2 Family Caspase Apoptosis Cancer
    BRD-810 is a potent and selective MCL1 inhibitor with a Kd of 0.3 nM. BRD-810 can specifically block the BH3 binding groove of MCL1, while having little effect on other anti-apoptotic proteins (such as Bcl-2, Bcl-xL). BRD-810 effectively destroys the MCL1-BAK complex (IC50 = 1.2 nM) in cancer cells, rapidly activates Caspase and induces cell apoptosis. BRD-810 can be used in the research of various cancers such as hematological tumors and solid tumors .
    BRD-810
  • HY-103566
    LY456236

    		mGluR EGFR p38 MAPK Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    LY456236 is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC50 of 0.145 μM. LY456236 can also inhibit EGFR, with an IC50 of 0.918 μM. LY456236 blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 can be used in epilepsy research .
    LY456236
  • HY-N0408R
    Picroside II (Standard)

    		Reference Standards NF-κB Reactive Oxygen Species (ROS) Apoptosis Influenza Virus Infection Neurological Disease Inflammation/Immunology Cancer
    Picroside II (Standard) is the analytical standard of Picroside II. This product is intended for research and analytical applications. Picroside II, an iridoid compound extracted from Picrorhiza, exhibits anti-inflammatory and anti-apoptotic activities. picroside II alleviates the inflammatory response in sepsis and enhances immune function by inhibiting the activation of NLRP3 inflammasome and NF-κB pathways . Picroside II is an antioxidant, exhibits a significant neuroprotective effect through reducing ROS production and protects the blood-brain barrier (BBB) after cerebral ischemia-reperfusion (CI/R) injury. Picroside II has antioxidant, anti-inflammatory, immune regulatory, anti-virus and other pharmacological activities .
    Picroside II (Standard)
  • HY-110073
    iMAC2 hydrochloride

    		Apoptosis Inflammation/Immunology Cancer
    iMAC2 hydrochloride is a potent MAC (mitochondrial apoptosis-induced channel) inhibitor, with an IC50 of 28 nM and a LD50 of 15000 nM. iMAC2 hydrochloride shows anti-apoptotic effect. iMAC2 hydrochloride blocks cytochrome c release .
    iMAC2 hydrochloride
  • HY-103272
    iMAC2

    		Apoptosis Inflammation/Immunology Cancer
    iMAC2 is a potent MAC inhibitor with an IC50 of 28 nM and an LD50 of 15000 nM. iMAC2 shows anti-apoptotic effect. iMAC2 blocks cytochrome c release .
    iMAC2
  • HY-B0612AR
    Lercanidipine hydrochloride (Standard)

    		Reference Standards Calcium Channel Apoptosis Reactive Oxygen Species (ROS) p38 MAPK NF-κB Cardiovascular Disease Neurological Disease
    Lercanidipine (hydrochloride) (Standard) is the analytical standard of Lercanidipine (hydrochloride). This product is intended for research and analytical applications. Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
    Lercanidipine hydrochloride (Standard)
  • HY-W707863
    Lercanidipine-d3

    		Reactive Oxygen Species (ROS) Neurological Disease
    Lercanidipine-d3 is the deuterium labeled Lercanidipine (HY-B0612). Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
    Lercanidipine-d3
  • HY-155759
    HMGB1-IN-2

    		NF-κB Interleukin Related Caspase Apoptosis Inflammation/Immunology Cancer
    HMGB1-IN-2 (compound 15) is an inhibitor of highly conserved nuclear protein (HMGB1), showing NO inhibitory effect with IC50 value of 20.2 μM in RAW264.7 cells. HMGB1-IN-2 (30 μM) decreases the level of IL-1 β, TNF-α, caspase-1 p20, inhibits the phosphorylation of NF-κB p65, exhibits anti-apoptotic activity. HMGB1-IN-2 (15 mg/kg; ip) relives kidney injury in septic acute kidney injury mouse. HMGB1-IN-2 inhibits Huh7 cells and A549 cells with IC50s of 77.0 μM, and 82.0 μM, respectively .
    HMGB1-IN-2
  • HY-161254
    ATPase-IN-3

    		Apoptosis MDM-2/p53 Inflammation/Immunology Cancer
    ATPase-IN-3 (compound 6) is a ATPase inhibitor. ATPase-IN-3 has Gastroprotective effect in ethanol-induced gastric ulcers by contribution of anti-apoptotic (BCL-2) and tumor suppressor (P53) proteins .
    ATPase-IN-3
  • HY-152193
    ChoKα inhibitor-4

    		Apoptosis Cancer
    ChoKα inhibitor-4 is a bioisosteric inhibitor of HChoK α1 (IC50=0.66 μM), with inhibitory and antiproliferative effect on cancer cells. ChoKα inhibitor-4 induces apoptosis via mitochondrial pathway, and reduces anti-apoptotic proteins expression .
    ChoKα inhibitor-4
  • HY-108635R
    C16-PAF (Standard)

    PAF (C16) (Standard)

    		 p38 MAPK MEK ERK Endogenous Metabolite Reference Standards Cardiovascular Disease Inflammation/Immunology
    C16-PAF (Standard) is the analytical standard of C16-PAF. This product is intended for research and analytical applications. C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability .
    C16-PAF (Standard)
  • HY-W717425
    SC-60

    		SHP1 STAT Caspase Apoptosis Bcl-2 Family CDK Survivin Drug Derivative Cancer
    SC-60 is a derivative of Sorafenib (HY-10201). SC-60 exerts its anti-tumor effect by activating the phosphatase activity of SHP-1, thereby inhibiting the STAT3 signaling pathway. SC-60 exhibits strong proliferation inhibitory activity in various hepatocellular carcinoma (HCC) cell lines. SC-60 downregulates the expression of downstream anti-apoptotic proteins (such as Bcl-2, Cyclin D1, Survivin), ultimately inducing caspase-dependent apoptosis. SC-60 significantly inhibits tumor growth in xenograft tumor models. SC-60 can be used for the study of HCC .
    SC-60
  • HY-123715
    Anticancer agent 255

    		Apoptosis Cancer
    Anticancer agent 255 is a monocarbonylated curcumin-1,2,3-oxazole conjugate with significant anticancer activity. The IC50 values of Anticancer agent 255 in prostate cancer cells PC-3 and DU-145 are 8.8μM and 9.5μM respectively. The IC50 values of Anticancer agent 255 against breast cancer cells MCF-7, MDA-MB-231 and 4T1 are 6μM, 10μM and 6.4μM, showing good anti-cancer activity Effect. Anticancer agent 255 can induce mitochondria-mediated apoptosis in cancer cells and prevent cell cycle progression. Anticancer agent 255 down-regulated the cell proliferation marker PCNA and inhibited the activation of cell survival proteins. Anticancer agent 255 up-regulated the pro-apoptotic protein Bax and down-regulated the anti-apoptotic protein Bcl-2 .
    Anticancer agent 255
  • HY-W027126
    Hepatoprotective agent-2

    		Apoptosis Metabolic Disease
    Hepatoprotective agent-2 (compound 2a), a 4-phenyl-tetrahydroquinoline derivative, displays a remarkable hepatoprotective effect. Hepatoprotective agent-2 has antiapoptotic activity. Hepatoprotective agent-2 notably prevents the chemically induced elevation of hepatic indicators associated with liver injury .
    Hepatoprotective agent-2
  • HY-N12669
    Curcumin monoglucoside

    		Bacterial Reactive Oxygen Species (ROS) Apoptosis JNK Caspase Neurological Disease
    Curcumin monoglucoside is a flavonoid derivative possessing antioxidant, anti-apoptotic, neuroprotective effects, and antibacterial activity. Curcumin monoglucoside can be used in research on Parkinson's disease.
    Curcumin monoglucoside
  • HY-P3600
    FIZZ-1 (32-51) (mouse)

    		Apoptosis Inflammation/Immunology
    FIZZ-1 (32-51) (mouse) is a cysteine-rich secretory protein that is highly expressed by macrophages, bronchial epithelial and type II alveolar epithelial cells (AEC) in allergic airway inflammation. FIZZ1 (32-51) (mouse) also shows an antiapoptotic effect on lung fibroblasts. FIZZ-1 (32-51) (mouse) can be used in the study of allergic pneumonia .
    FIZZ-1 (32-51) (mouse)
  • HY-N19425
    Pulsatilloside A

    		Apoptosis Metabolic Disease
    Pulsatilloside A is an anti-Apoptotic agent. Pulsatilloside A can be isolated from the roots of P. chinensis. Pulsatilloside A exerts a protective effect against apoptosis induced by sodium cyanide and glucose deprivation .
    Pulsatilloside A
  • HY-108521R
    HX531 (Standard)

    		Reference Standards RAR/RXR Apoptosis MDM-2/p53 Metabolic Disease Cancer
    HX531 (Standard) is the analytical standard of HX531 (HY-108521). This product is intended for research and analytical applications. HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities .
    HX531 (Standard)
  • HY-103566A
    LY456236 free base

    		mGluR EGFR p38 MAPK Apoptosis Neurological Disease
    LY456236 free base is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC50 of 0.145 μM. LY456236 free base can also inhibit EGFR, with an IC50 of 0.918 μM. LY456236 free base blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 free base can be used in epilepsy research .
    LY456236 free base
  • HY-103566R
    LY456236 (Standard)

    		Reference Standards mGluR EGFR p38 MAPK Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    LY456236 (Standard) is the analytical standard of LY456236 (HY-103566). This product is intended for research and analytical applications. LY456236 is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC50 of 0.145 μM. LY456236 can also inhibit EGFR, with an IC50 of 0.918 μM. LY456236 has anticonvulsant effects and blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 can be used in epilepsy research .
    LY456236 (Standard)
  • HY-138135
    OP-1118

    Fidaxomicin metabolite OP-1118

    		 NF-κB ERK Apoptosis Bacterial Infection
    OP-1118 (Fidaxomicin metabolite OP-1118) is an orally active dual inhibitor of NF-κB and ERK1/2, with low systemic plasma exposure, no accumulation, and primary excretion via feces. By inhibiting the phosphorylation of NF-κB and ERK1/2 and reducing the expression of pro-inflammatory cytokines, OP-1118 exerts significant anti-inflammatory, cytoprotective, anti-apoptotic and antibacterial activities. In Clostridium difficile infection models, OP-1118 effectively blocks toxin-mediated intestinal inflammation, cell rounding, histological damage and apoptosis, and its protective effect can be reversed by PMA (HY-18739) .
    OP-1118
  • HY-20888
    3'-Methoxy-4'-nitroflavone

    MNF

    		 Aryl Hydrocarbon Receptor Cytochrome P450 Apoptosis Akt ERK TGF-beta/Smad Neurological Disease Inflammation/Immunology Cancer
    3'-Methoxy-4'-nitroflavone (MNF) is a specific aryl hydrocarbon receptor (AhR) antagonist. 3'-Methoxy-4'-nitroflavone activates AhR by inhibiting CYP1, the metabolic enzyme of the endogenous ligand FICZ (HY-12451), leading to the accumulation of FICZ. 3'-Methoxy-4'-nitroflavone reverses the anti-apoptotic effect of TCDD, attenuates the activation of Akt and Erk1/2 kinases and the expression of TGFα induced by TCDD. 3'-Methoxy-4'-nitroflavone can be used in research related to breast tumor promotion, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease .
    3'-Methoxy-4'-nitroflavone
  • HY-N18905
    α-D-Glucosyl hesperidin

    		Apoptosis Bcl-2 Family Caspase SOD Endocrinology
    α-D-Glucosyl hesperidin is an orally effective structural modification derivative of Hesperidin (HY-15337) with anti-apoptotic (apoptosis) and antioxidant activities. α-D-Glucosyl hesperidin upregulates the expression of the Bcl-2 gene, while downregulating the expressions of the Bax and caspase-3 genes. α-D-Glucosyl hesperidin increases total antioxidant capacity, SOD and catalase levels, and decreases malondialdehyde and glutathione levels. α-D-Glucosyl hesperidin improves sperm motility, viability and plasma membrane function, while restoring reproductive organ weight and seminiferous tubule structure. α-D-Glucosyl hesperidin increases fertility index and exerts a synergistic protective effect with Proanthocyanidins (HY-N0794) in male rats with testicular ischemia-reperfusion injury. α-D-Glucosyl hesperidin can be used in the research of testicular ischemia-reperfusion injury .
    α-D-Glucosyl hesperidin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: